Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Francisco Lopez-Tapia"'
Autor:
Yinsong Zhu, Peibin Yue, Cody F. Dickinson, Justin K. Yang, Kyrstin Datanagan, Ning Zhai, Yi Zhang, Gabriella Miklossy, Francisco Lopez-Tapia, Marcus A. Tius, James Turkson
Publikováno v:
Cell Death and Disease, Vol 13, Iss 12, Pp 1-14 (2022)
Abstract Dysregulated gene expression programs and redox and metabolic adaptations allow cancer cells to survive under high oxidative burden. These mechanisms also represent therapeutic vulnerabilities. Using triple-negative breast cancer (TNBC) as a
Externí odkaz:
https://doaj.org/article/d34229ea9bfc4181a22308db8241c982
Autor:
James Turkson, Marcus A. Tius, Yuan Chen, Tyvette Hilliard, Chih-Hong Chen, Yifei Li, David Paladino, Francisco Lopez-Tapia, Peibin Yue
Supplementary Materials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eff77828e218a5015581fd5e16140f1
https://doi.org/10.1158/0008-5472.22408455
https://doi.org/10.1158/0008-5472.22408455
Autor:
James Turkson, Marcus A. Tius, Yuan Chen, Tyvette Hilliard, Chih-Hong Chen, Yifei Li, David Paladino, Francisco Lopez-Tapia, Peibin Yue
STAT3 offers an attractive target for cancer therapy, but small-molecule inhibitors with appealing pharmacologic properties have been elusive. Here, we report hydroxamic acid–based and benzoic acid–based inhibitors (SH5-07 and SH4-54, respectivel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2685919e413c2073f3397cc0c16dd175
https://doi.org/10.1158/0008-5472.c.6507540
https://doi.org/10.1158/0008-5472.c.6507540
Autor:
James Turkson, Marcus A. Tius, Yuan Chen, Tyvette Hilliard, Chih-Hong Chen, Yifei Li, David Paladino, Francisco Lopez-Tapia, Peibin Yue
Supplementary Figures S1-8. Fig. S1: EMSA analysis of Stat3 DNA-binding activity in vitro showing the effect of BP-1-102. Fig. S2: Effects of SH5-07, SH4-54 or BP-1-102 on Stat3 tyrosine and serine phosphorylation in tumor cells and on Stat3 DNA-bind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0aad91b9f2cfc352b40b2cfe9ebd0cff
https://doi.org/10.1158/0008-5472.22408458.v1
https://doi.org/10.1158/0008-5472.22408458.v1
Autor:
Peibin Yue, Francisco Lopez-Tapia, Yinsong Zhu, Nagendra Verma, Felix Alonso-Valenteen, Simoun Mikhael, Lali Medina-Kauwe, Marcus Tius, James Turkson
Publikováno v:
Cancer Research. 82:5476-5476
Anticancer drugs that directly target Signal Transducer and Activator of Transcription (Stat)3 have remained elusive. We present azetidine-based small molecules as a new class of potent Stat3 inhibitors. Compounds H172 and H182 have potency (IC50) of
Autor:
Yinsong Zhu, Cody F. Dickinson, Justin Yang, Kyrstin Datanagan, Ning Zhai, Peibin Yue, Francisco Lopez-Tapia, Marcus A. Tius, James Turkson
Publikováno v:
Cancer Research. 82:5482-5482
Bioactive natural products have led to new drugs or been the inspiration for developing new treatments. Signal transducer and activator of transcription (STAT)3 is a an oncogene that has been implicated in many human cancers. We report that the hirsu
Autor:
Peibin Yue, Yinsong Zhu, Christine Brotherton-Pleiss, Wenzhen Fu, Nagendra Verma, Jasmine Chen, Kayo Nakamura, Weiliang Chen, Yue Chen, Felix Alonso-Valenteen, Simoun Mikhael, Lali Medina-Kauwe, Kathleen M. Kershaw, Maria Celeridad, Songqin Pan, Allison S. Limpert, Douglas J. Sheffler, Nicholas D.P. Cosford, Stephen L. Shiao, Marcus A. Tius, Francisco Lopez-Tapia, James Turkson
Publikováno v:
Cancer Letters. 534:215613
Signal transducer and activator of transcription (Stat)3 is a valid anticancer therapeutic target. We have discovered a highly potent chemotype that amplifies the Stat3-inhibitory activity of lead compounds to levels previously unseen. The azetidine-
Autor:
James Turkson, Christine Brotherton-Pleiss, Marcus A. Tius, Peibin Yue, Fu Wenzhen, Francisco Lopez-Tapia
Publikováno v:
Cancer Research. 79:4792-4792
The development of inhibitors of Signal transducer and activator of transcription (STAT) 3 for clinical application has faced significant challenges and to date there are no suitable STAT3 small molecule inhibitors in the clinic. We report a novel cl
Autor:
Francisco Lopez-Tapia, Marcus A. Tius, Christine Brotherton-Pleiss, Peibin Yue, James Turkson
Publikováno v:
Molecular Cancer Therapeutics. 17:B137-B137
We investigated the molecular determinants for the activity of the previously reported salicylic BP-1-102 (IC50 6.8 ± 2.5 μM), benzoic SH4-54 (IC50 4.4 ± 0.3 μM), and benzohydroxamic acid SH5-07 (IC50 3.9 ± 0.6 μM) small-molecule STAT3 inhibito
Autor:
Christine Brotherton-Pleiss, Francisco Lopez-Tapia, James Turkson, Marcus A. Tius, Peibin Yue
Publikováno v:
Cancer Research. 76:LB-058
Benzoic acid, salicylic acid and hydroxamic acid-based small molecules have been reported that inhibit Stat3 activation. However, the structural basis for their Stat3-inhibitory activities are not clearly defined. To investigate the molecular determi